Adrenocortical Carcinoma clinical trials
The registry lists 94 studies for Adrenocortical Carcinoma across more than 10 countries. 26 are recruiting or about to start. 64 of them are mainly about Adrenocortical Carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Adrenocortical Carcinoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (18) · University of Wuerzburg (6) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (5) · Children's Oncology Group (4) · M.D. Anderson Cancer Center (3) · Corcept Therapeutics (3) · Memorial Sloan Kettering Cancer Center (2) · INSYS Therapeutics Inc (2)
What is being tested here
Drugs under test in Adrenocortical Carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Pembrolizumab | 2 | 0 | 6 |
| Mitotane | 2 | 1 | 4 |
| Cisplatin | 1 | 3 | 9 |
| Doxorubicin | 1 | 1 | 4 |
| Cabozantinib | 1 | 0 | 3 |
| Etoposide | 1 | 2 | 3 |
| Carfilzomib | 1 | 0 | 1 |
| Ivonescimab | 1 | 0 | 1 |
| Immunocytokine NHS-IL12 | 1 | 0 | 1 |
| Dostarlimab | 1 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 6 open · Tyrosine kinase inhibitors (TKIs) 2 open · Antimitotic agents 4
Coming up
0phase 3 studies under way
14studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome · Corcept Therapeutics
- Dec 2026Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma · Columbia University
- Dec 2026Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors · Dana-Farber Cancer Institute
- Dec 2026Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) · Shanghai Jiao Tong University School of Medicine
- Dec 2026Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) · National Cancer Institute (NCI)
- Dec 2026Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma · West China Hospital
- Feb 2027Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma · National Cancer Center, Korea
- Mar 2027Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma · Sun Yat-sen University
- Mar 2027A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) · Eisai Co., Ltd.
- May 2027Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. · Maria Sklodowska-Curie National Research Institute of Oncology
Who these studies take
Of the 21 Adrenocortical Carcinoma studies recruiting now, 15 (71%) set no upper age limit and 2 (10%) stop at 75 or younger. 4 (19%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (14%) | 3 (14%) |
| 18 | 20 (95%) | 20 (95%) |
| 30 | 21 (100%) | 21 (100%) |
| 40 | 21 (100%) | 21 (100%) |
| 50 | 21 (100%) | 21 (100%) |
| 65 | 21 (100%) | 21 (100%) |
| 75 | 20 (95%) | 20 (95%) |
| 85 | 19 (90%) | 19 (90%) |
Across all 94 studies, recruiting or not: 15% stop at 75 or younger and 10% at 65; 23% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 → or search them.
- Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingNCT07715903Phase 11 country
- Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaRecruitingNCT06487481Phase 11 country
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 11 country
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerRecruitingNCT06900595Phase 21 country
- PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaRecruitingNCT05286814Phase 21 country
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingNCT07743138Phase 21 country
- German Adrenocortical Carcinoma RegistryRecruitingNCT004536741 country
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT030502681 country
- A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerRecruitingNCT07189403Phase 13 countries
- Adrenal Tumors - Pathogenesis and TherapyRecruitingNCT006692661 country
- Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaRecruitingNCT06066333Phase 21 country
- Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)RecruitingNCT06141369Not applicable1 country
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 11 country
- Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingNCT06006013Phase 21 country
- Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex CarcinomaRecruitingNCT073356791 country
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingNCT06333314Phase 21 country
- Cemiplimab as Maintenance Treatment for Advanced Adrenocortical CancerRecruitingNCT07085572Phase 21 country
- A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.Not yet recruitingNCT07141147Not applicable1 country
- Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaRecruitingNCT06831175Phase 21 country
- Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical CarcinomaRecruitingNCT06587802Phase 21 country
- Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)RecruitingNCT05913427Phase 21 country
- Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical CarcinomaRecruitingNCT04318730Phase 21 country
- Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World DataRecruitingNCT062294051 country
- Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted AdrenalectomyRecruitingNCT060500571 country
- The Adverse Event of Mitotane Therapy in Patients With Adrenocortical CarcinomaNot yet recruitingNCT05839886
- A Prospective Cohort Study for Patients With Adrenal DiseasesEnrolling by invitationNCT034742371 country
- Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Active, not recruitingNCT05563467Phase 21 country
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 210 countries
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 21 country
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 21 country
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- Preclinical Study Towards an Immunotherapy in Adrenocortical CarcinomaActive, not recruitingNCT004575871 country
- Evaluation of Side Effects of MitotaneActive, not recruitingNCT005681391 country
- Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical CarcinomaActive, not recruitingNCT03127774Phase 21 country
- Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaActive, not recruitingNCT02673333Phase 21 country
- Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)Active, not recruitingNCT043581071 country
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 11 country
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/28 countries
- Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical CarcinomaActive, not recruitingNCT05036434Phase 21 country
- Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing YieldCompletedNCT023246471 country
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 13 countries
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaTerminatedNCT05634577Phase 21 country
- Phase 1 Study of 68Ga-R8760TerminatedNCT05999292Phase 11 country
- A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedNCT00924989Phase 39 countries
- Milademetan in Advanced/Metastatic Solid TumorsTerminatedNCT05012397Phase 21 country
- Cabozantinib in Advanced Adrenocortical CarcinomaActive, not recruitingNCT03612232Phase 21 country
- Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInomaCompletedNCT03723941Phase 31 country
- Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical TumorCompletedNCT00304070Phase 34 countries
- Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 11 country
- European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical CarcinomaStatus unknownNCT057635241 country